Mesa Laboratories Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Mesa Laboratories ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 0.48%.

Wichtige Informationen

0.5%

Dividendenausschüttung

-1%

Ausschüttungsquote

Durchschnittlicher Branchenertrag	0.3%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	US$0.640
Gewinn pro Aktie	-US$46.27
Prognose der Dividendenrendite	0.5%

Aktuelle Dividendenentwicklung

Recent updates

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Jul 29

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

May 03

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

May 06

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: MLAB zahlt keine nennenswerte Dividende für den Markt US, daher muss nicht geprüft werden, ob die Zahlungen stabil sind.

Wachsende Dividende: MLAB zahlt keine nennenswerte Dividende für den Markt US, daher ist es nicht notwendig zu prüfen, ob die Zahlungen steigen.

Dividendenrendite im Vergleich zum Markt

Mesa Laboratories Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von MLAB im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (MLAB)	0.5%
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Life Sciences)	0.3%
Analystenprognose (MLAB) (bis zu 3 Jahre)	0.5%

Bemerkenswerte Dividende: MLABDie Dividende des Unternehmens (0.49%) ist im Vergleich zu den unteren 25 % der Dividendenzahler auf dem Markt US (1.45%) nicht bemerkenswert.

Hohe Dividende: MLABDie Dividende des Unternehmens (0.49%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt US (4.48%) niedrig.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: MLAB zahlt keine nennenswerte Dividende für den Markt US.

Barausschüttung an die Aktionäre

Cashflow-Deckung: MLAB zahlt keine nennenswerte Dividende für den Markt US.

Mesa Laboratories Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Upcoming dividend of US$0.16 per share at 0.7% yield

Recent updates

Insider notifies of intention to sell stock

Price target increased by 10% to US$130

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Fourth quarter dividend of US$0.16 announced

Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024

Upcoming dividend of US$0.16 per share

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Consensus EPS estimates upgraded to US$0.055 loss

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Insider notifies of intention to sell stock

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Upcoming dividend of US$0.16 per share at 0.7% yield

Price target decreased by 17% to US$115

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Price target decreased by 8.9% to US$139

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

CEO, President & Director notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.5% yield

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Now 20% undervalued after recent price drop

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Consensus EPS estimates increase by 14%

Now 21% undervalued after recent price drop

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

Price target decreased by 11% to US$178

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.4% yield

VP, CFO & Chief Accounting Officer exercised options and sold US$132k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023

Upcoming dividend of US$0.16 per share

Now 21% undervalued after recent price drop

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.

Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee

Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)